ETHK Labs (1931) is a CN-listed Healthcare company in Medical - Distribution with a market capitalization of HK
.0B, trading at HK$0.63 on the HKSE. This SniperIQ fundamentals page covers ETHK Labs's valuation (P/E 25.3x, P/B 0.3x), profitability (net margin 1.2%), revenue (¥2.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market CapHK
.0B
P/E (TTM)25.3x
Net Margin1.2%
Revenue (FY25)¥2.8B
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is ETHK Labs's market cap?
ETHK Labs (1931) has a market capitalization of approximately HK
.0B, trading at HK$0.63 on the HKSE. Market cap moves with the live share price.
What is ETHK Labs's P/E ratio?
ETHK Labs's trailing twelve-month P/E ratio is 25.3x, with a price-to-book (P/B) of 0.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is ETHK Labs?
ETHK Labs runs a net profit margin of 1.2%, a gross margin of 20.1%, and an operating margin of 5.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does ETHK Labs generate?
ETHK Labs reported revenue of ¥2.8B for fiscal year 2025, with net income of ¥35M and earnings per share (EPS) of 0.0216. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does ETHK Labs pay a dividend?
ETHK Labs does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is ETHK Labs financially healthy?
ETHK Labs carries a debt-to-equity ratio of 0.65x and a current ratio of 1.34x, with a market beta of -0.49. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is ETHK Labs a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For ETHK Labs (1931) the key facts are: market cap HK
.0B, P/E 25.3x, revenue ¥2.8B, 52-week range 0.56-12.86. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track ETHK Labs's full fundamentals live
Get ETHK Labs's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.